# Abuse-Deterrant Opioid Formulations & Comparators

_____

[Detailed study overview](https://www.opioiddata.org/studies/counfounding-opioid-safety-studies/) at the full project site [OpioidData.org](https://www.opioiddata.org)
<br>

_____

##### **Full list of NDCs for abuse-deterrent formulations of opioids for analytic purposes can be found [here](ADF_NDCs.csv)**

_____

This document contains information on abuse-deterrent formulations (ADF) of opioids.
_____

### Abuse-Deterrent Formulations

|Drug Name|NDA#|Categories of Evidence|Intended Route of Deterrence|Documentation|Status|ER/IR|Approved as ADF?|
|---|---|-----------|---------|--------|---|---|---|
|OxyContin|22-272|Categories 1-4|Intravenous, intranasal|[Drugs@FDA: OxyContin](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022272)<br><br>[FDA AdCom: September 10-11, 2020](https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-10-11-2020-joint-meeting-drug-safety-and-risk-management-advisory-committee-and-anesthetic#event-materials)<br><br>[OxyContin NDCs](OxyContin/oxycontin_NDCs.csv)<br><br>[OxyContin Documentation](OxyContin)|Active|ER|Yes|
|Hysingla ER|206627|**Intranasal & oral:** Category 1, Category 3<br>**Injection:** Category 1|Intravenous, intranasal, oral|[Drugs@FDA: Hysingla ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206627)<br><br>[Hysingla NDCs](Hysingla_ER/hysingla_NDCs.csv)<br><br>[Hysingla Documentation](Hysingla_ER)|Active|ER|Yes|
|MorphaBond ER|206544|**Injection:** Category 1<br>**Intranasal:** Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: MorphaBond ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206544)<br><br>[MorphaBond NDCs](MorphaBond_ER/morphabond_NDCs.csv)<br><br>[MorphaBond Documentation](MorphaBond_ER)|Discontinued|ER||
|Xtampza ER|208090|Categories 1-3|Intravenous, intranasal, oral|[Drugs@FDA: Xtampza ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208090)<br><br>FDA AdCom: September 11, [2015](http://wayback.archive-it.org/7993/20170112100735/http://www.fda.gov/AdvisoryCommittees/Calendar/ucm457905.htm)<br><br>[Xtampza NDCs](Xtampza_ER/xtampza_NDCs.csv)<br><br>[Xtampza Documentation](Xtampza)|Active|ER|Yes|
|RoxyBond|209777|Categories 1-3|Intravenous, intranasal|[Drugs@FDA: RoxyBond](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209777)<br><br>FDA AdCom: April 5, [2017](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2017-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[RoxyBond Documentation](RoxyBond)|Discontinued|IR|Yes: Intravenous, intranasal|
|Embeda|022321|**Oral & Intranasal:** Category 1, Category 2, Category 3|Oral, intranasal|[Drugs@FDA: Embeda](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process)<br><br>[Embeda NDCs](Embeda/embeda_NDCs.csv)<br><br>[Embeda Documentation](Embeda)|Discontinued|ER|Yes|
|Arymo ER|208603|Categories 1-3|Oral, intravenous, intranasal|[Drugs@FDA: Arymo ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process)<br><br>FDA AdCom: August 4, [2016](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2016-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Arymo NDCs](Arymo_ER/arymo_NDCs.csv)<br><br>[Arymo Documentation](Arymo)|Discontinued|ER|Yes: Oral, intravenous, intranasal|
|Targiniq|205777|Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: Targiniq](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process)<br><br>[Targiniq Documentation](Targiniq)|Discontinued|ER||
|Troxyca ER|207621|Category 1, Category 2, Category 3|Oral, intranasal|[Drugs@FDA: Troxyca ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process)<br><br>FDA AdCom: June 8, [2016](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2016-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Troxyca Documentation](Troxyca)|Discontinued|ER|Yes:Oral, intranasal, intravenous|
|Oxaydo/Oxecta|202080|Category 3|Intranasal|[Drugs@FDA: Oxaydo](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process)<br><br>[Oxaydo/Oxecta NDCs](Oxaydo/oxaydo_NDCs.csv)<br><br>[Oxaydo Documentation](Oxaydo)|Active|IR||
|Aximris XR|209653|Categories 1-3|Oral, intravenous, intranasal|FDA AdCom: January 15, [2020](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2017-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>FDA AdCom: July 26, [2017](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2017-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Aximris XR Documentation](Aximris_XR)|Inactive|ER|No|
|Opana ER|201655|Categories 1-4|Intranasal, intravenous|FDA AdCom: March 13-14, [2020](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2017-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Opana Documentation](Opana_ER)|Inactive|ER|No|
|Vantrela ER|207975|Categories 1-3|Oral, intranasal, intravenous|FDA AdCom: June 7, [2016](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2016-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Vantrela ER Documentation](Vantrela_ER)|Inactive|ER|Yes: Oral, intranasal, intravenous|
|Apadaz|208653|Categories 1-3|Oral, intranasal, intravenous, smoking|FDA AdCom: May 5, [2016](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2016-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Apadaz Documentation](Apadaz)|Inactive|IR|No|
|Remoxy ER|22324|Categories 1-3|Intranasal, intravenous, smoking|FDA AdCom: June 26, [2018](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2018-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Remoxy ER Documentation](Remoxy_ER)|Inactive|ER|No|
|Avridi|206830|Categories 1-3|Intranasal, intravenous|FDA AdCom: September 10, [2015](http://wayback.archive-it.org/7993/20170111202121/http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/ucm433361.htm)<br><br>[Avridi Documentation](Avridi)|Inactive|IR|No|

_____

